Transcription of Public Assessment Report Decentralised Procedure …
{{id}} {{{paragraph}}}
Example: biology
Public Assessment Report Decentralised Procedure …
PAR Or listat Mylan 60 mg capsules, har d UK/H/5278/001/DC 1 Public Assessment Report Decentralised Procedure Orlistat Mylan 60 mg capsules, hard (Orlistat) Procedure No: UK/H/5278/001/DC UK Licence No: PL 04569/1359 Generics (UK) Limited (trading as Mylan) PAR Or listat Mylan 60 mg capsules, har d UK/H/5278/001/DC 2 LAY SUMMARY Orlistat Mylan 60 mg capsules, hard (orlistat, hard capsules, 60 mg) This is a summary of the Public Assessment Report (PAR) for Orlistat Mylan 60 mg capsules, hard (PL 04569/1359; UK/H/5278/001/DC). It explains how Orlistat Mylan 60 mg capsules, hard w as assessed and its authorisation recommended, as well as its conditions of use. It is not intended to provide practical advice on how to use Orlistat Mylan 60 mg capsules, hard. For practical information about using Orlistat Mylan 60 mg capsules, hard, patients should read the package leaflet or contact their doctor or pharmacist.
PAR Orlistat Mylan 60 mg capsules, hard UK/H/5278/001/DC 1. Public Assessment Report . Decentralised Procedure . Orlistat Mylan 60 mg capsules, hard (Orlistat) Procedure No: UK/H/5278/001/DC
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Related search queries
DECENTRALISED PROCEDURE MEMBER STATES’, DECENTRALISED PROCEDURE MEMBER STATES’ STANDARD, Procedure, Decentralised Procedure, FLOW CHART OF THE DECENTRALISED, FLOW CHART OF THE DECENTRALISED PROCEDURE, All About Regulatory Affairs, Member States, Commission Regulation, Quick Response (QR) codes in the labelling and, Decentralised, EU regulatory framework and the role, REGISTER OF MEDICINAL, Register of medicinal products - frequently asked questions, QRD Human Product Information Template